Ipilimumab and Nivolumab as Adjuvant Treatment of Mucosal Melanoma
Status:
Recruiting
Trial end date:
2023-04-01
Target enrollment:
Participant gender:
Summary
This is a single arm phase II clinical trial of Ipilimumab and Nivolumab in patients with
resected mucosal melanoma. Ipilimumab (1 mg/kg) and Nivolumab (3 mg/kg) will be administered
Day 1 of a 21-day cycle in Cycles 1-4 and then nivolumab 480 mg will be administered Day 1 of
a 28-day cycle for Cycles 5-15 (maximum of 15) or until disease recurrence or intolerance
before completion of 15 cycles.
Phase:
Phase 2
Details
Lead Sponsor:
Robert R. McWilliams, MD
Collaborators:
Bristol-Myers Squibb Hoosier Cancer Research Network